Sessions

Diurnal and racial variance of white blood cell parameters in early phase clinical trials: a retrospective analysis of pooled data from multiple phase I trials

[Speaker] Jorg Taubel:1,2
[Co-author] Jonathan Bowen:1, Daniela Cimmaruta:3, Dilshat Djumanov:1, Ulrike Lorch:1, Simon Coates:1, Georg Ferber:4
1:Richmond Pharmacology, St Georges University of London, UK, 2:St. George's University of London, UK, 3:Department of Experimental Medicine, Second University of Naples, Italy, 4:Statistik Georg Ferber GmbH, 4125 Riehen, Switzerland

Platelet reactivity in an elderly and healthy population

[Speaker] Melissa V Chan:1
[Co-author] Temo Barwari:2, Jennifer E Huffman:3, Paul C Armstrong:1, Peter Santer:4, Stefan Kiechl:5, Johann Willeit:5, Manuel Mayr:2, Andrew D Johnson:3, Timothy D Warner:1
1:The Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK, 2:King's British Heart Foundation Centre, King's College London, UK, 3:The National Heart, Lung and Blood Institute's Framingham Heart Study, USA, 4:Department of Laboratory Medicine, Bruneck Hospital, Italy, 5:Department of Neurology, Medical University Innsbruck, Austria

Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: A Danish nationwide cohort study

[Speaker] Maurizio Sessa:1
[Co-author] Annamaria Mascolo:1, Rikke N Mortensen:2, Mikkel P Andersen:2, Giuseppe Mc Rosano:3, Annalisa Capuano:1, Francesco Rossi:1, Gunnar Gislason:5, Henrik Enghusen-Poulsen:4, Christian Torp-Pedersen:2
1:University of Campania “L. Vanvitelli”, Italy, 2:Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark, 3:San Raffaele Pisana Hospital IRCCS, Rome, Italy, 4:Laboratory of Clinical Pharmacology, Rigshospitalet, Copenhagen, Denmark, 5:The Danish Heart Foundation, Copenhagen K, Copenhagen, Denmark

The initial results of a new oral thrombolytic clinical trial

[Speaker] Pavel Madonov:1
[Co-author] Aleksandr Dygai:2, Vadim Zhdanov:2, Stanislav Leontyev:3, Sergey Zotov:4, Maksim Ufimtsev:4, Svetlana Mishenina:1, Dmitrii Kinsht:1
1:Novosibirsk State Medical University, Russian Federation, Russia, 2:E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Russia, 3:Pirogov Russian National Research Medical University, Russia, 4:South Ural State Medical University, Russia

VEriciguat NItroglycerin Clinical IntEraction (VENICE): A phase 1, multicenter, randomized, placebo-controlled, double-blind group-comparison study in patients with stable coronary artery disease to evaluate tolerability and blood pressure effects of nitroglycerin after pre-treatment with multiple oral doses of vericiguat

[Speaker] Gerd Mikus:1
[Co-author] Michael F Boettcher:2, Hans-Dirk Duengen:3, Frank Donath:4, Nikos Werner:5, Petra A Thuermann:6, Mahir Karakas:7, Boris Weimann:8, Tanja Koch:2, Corina Becker:2
1:University of Heidelberg, Heidelberg, Germany, 2:Bayer AG, Germany, 3:Charite Universitaetsmedizin Berlin, Berlin, Germany, 4:Socra Tec R&D GmbH, Erfurt, Germany, 5:University Hospital Bonn, Bonn, Germany, 6:HELIOS Klinikum Wuppertal GmbH, Wuppertal, Germany, 7:University Heart Center Hamburg, Hamburg, Germany, 8:Chrestos Concept GmbH & Co. KG, Essen, Germany

Advanced Search